DOCSLIB.ORG

PDE5 Inhibitors Beyond Erectile Dysfunction

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PDE5 Inhibitors Beyond Erectile Dysfunction International Journal of Impotence Research (2007) 19, 533–543 & 2007 Nature Publishing Group All rights reserved 0955-9930/07 $30.00 www.nature.com/ijir REVIEW PDE5 inhibitors beyond erectile dysfunction P Sandner, J Hu¨ tter, H Tinel, K Ziegelbauer and E Bischoff Product-Related Research, Bayer HealthCare, Wuppertal, Germany The phosphodiesterase type-5 (PDE5) inhibitors sildenafil, vardenafil and tadalafil are widely used first-line therapy for erectile dysfunction (ED). Since the advent of sildenafil in 1998, more than 40 million men worldwide have been successfully treated with these compounds. The safety and high tolerability of PDE5 inhibitors make them an attractive tool to investigate further physiological functions of PDE5, for example the modulation of intracellular cyclic GMP (cGMP) pools. As cGMP is a key component of intracellular signaling this may provide novel therapeutic opportunities beyond ED even for indications in which chronic administration is necessary. The approval of sildenafil for the treatment of pulmonary hypertension in 2005 was a notable success in this area of research. A number of other potential new indications are currently in various phases of preclinical research and development. In recent years, extensive but very heterogeneous information has been published in this field. The aim of this review is to summarize existing preclinical and clinical knowledge and critically discuss the evidence to support potential future indications for PDE5 inhibitors. International Journal of Impotence Research (2007) 19, 533–543; doi:10.1038/sj.ijir.3901577; published online 12 July 2007 Keywords: lower urinary tract symptoms; benign prostate syndrome; premature ejaculation; Raynaud’s disease; Peyronie’s disease; heart failure Introduction cGMP-driven cascade of reactions. Ultimately, these pathways decrease intracellular calcium levels, It is well established that nitric oxide (NO) and thereby promoting relaxation of smooth muscle cells natriuretic peptides increase intracellular cGMP and a variety of other calcium-dependent pro- levels by stimulation of the soluble and membrane- cesses.3 Since inhibitors of PDE5 raise intracellular bound guanylate cyclase, respectively. This cGMP cGMP levels, the effects will be much more formation is the initial step of a ubiquitous bio- pronounced under conditions when cGMP forma- chemical pathway, regulating the cardiovascular, tion is already increased. Strong evidence to support central and peripheral nervous system.1 Phospho- this concept is the highly efficacious treatment of diesterases (PDEs) are intracellular enzymes that erectile dysfunction (ED) with PDE5 inhibitors.4 specifically catalyze the hydrolysis of the second Sexual stimulation induces a selective vasorelaxa- messengers cAMP and cGMP to the inactive meta- tion in penile tissue, which is predominantly bolites AMP and GMP. Among the 11 families of mediated by the release of NO in the cavernous PDEs a number are able to hydrolyze cGMP, but only nerve endings, the endothelium of penile arteries PDE5 exclusively catalyses the breakdown of and the corpora cavernosa. Relaxation is induced by cGMP.2 By counterbalancing cGMP production by the subsequent formation of cGMP. By preventing guanylate cyclases, PDE5 is able to decrease cGMP degradation of cGMP, PDE5 inhibitors reinforce this levels very effectively. Thus PDE5 inhibition in- physiological mechanism very efficaciously and creases intracellular cGMP levels and initiates a induce the appropriate vasorelaxation necessary to obtain an erection. It is the regulatory mechanism that forms the basis for the triumphal success of PDE5 inhibitors in the treatment of ED. Correspondence: Dr E Bischoff, Product-Related Research, Bayer HealthCare, Aprather Weg 18a, Wuppertal 42096, Three compounds are available worldwide, three Germany. others may enter into the market during the next E-mail: [email protected] years (Table 1). The wide, safe use of PDE5 Received 13 February 2007; revised 10 May 2007; inhibitors, together with an increasing understand- accepted 25 May 2007; published online 12 July 2007 ing of cGMP-regulated mechanisms, have triggered a PDE5 inhibitors beyond erectile dysfunction P Sandner et al 534 Table 1 Approved and emerging PDE5 inhibitors inhibitors. There is a large body of preclinical and clinical evidence showing that PDE5 inhibitors Compound Company Status reduce vascular resistance in the pulmonary circu- lation and pressure in the pulmonary arteries. The Sildenafil Pfizer Approved for ED and PAH rationale is based on the hypothesis that oxygena- Vardenafil Bayer AG Approved for ED Tadalafil Eli Lilly Approved for ED tion of the alveoli stimulates release of NO, which Udenafil5 Dong Pharmaceutical Approved for ED in causes a local relaxation of pulmonary resistance Co Ltd Korea, Phase 3 in US vessels. Inhibition of cGMP cleavage results in 6 Avanafil Tanabe Seiyaku, Phase 2 amplification of this regulatory pathway, causing licensed by Vivus SLX-21017 Surface Logics Phase 1 increased vasodilation without inducing a ventila- tion–perfusion mismatch. Abbreviations: ED, erectile dysfunction; PAH, pulmonary hyper- In animal models, such as the monocrotaline- tension; PDE5, phosphodiesterase type-5. induced pulmonary hypertension (PAH) in rats, it has been demonstrated that the PDE5 inhibitor sildenafil reduces pulmonary arterial pressure and number of attempts to find new applications for right heart hypertrophy.19 Moreover, it has been these agents. It has been shown that besides corpus shown that inhibition of cGMP cleavage by sildena- cavernosum, PDE5 is also expressed in smooth fil reduces the hypoxia induced rise in pulmonary muscles of the systemic vasculature,8 prostate,9 pressure and partially reverses pulmonary artery bladder,10 cardiac tissues,11,12 brain and plate- muscularization.20 lets,13,14 which imply additional target tissues for In clinical studies sildenafil also has been shown PDE inhibitors. The aim of this paper was to to be a safe and effective drug for patients with PAH. critically review and discuss recent findings in this A small crossover study showed that sildenafil field, and highlight possible future therapeutic uses improved exercise time and cardiac output signifi- of PDE5 inhibitors beyond ED. cantly, whereas pulmonary arterial pressure was only slightly decreased.21 In the SUPER-1 (Sildena- fil Use in Pulmonary Hypertension) study (a large, PDE5 inhibitors to treat cardiovascular randomized, controlled, multinational trial) silde- nafil significantly improved exercise capacity, func- diseases and endothelial dysfunction tional class and hemodynamic parameters and was well-tolerated.22 On the basis of these data, sildena- PDE5 inhibitors may be optimally suited for the fil was approved in 2005 by the United States Food treatment of cardiovascular diseases, due to their and Drug Administration and the European Agency mechanism of action. Increases in intracellular for the Evaluation of Medicinal Products for the cGMP levels cause a relaxation of vascular smooth treatment of patients with PAH. muscles. This is not only a generalized vasodilation, since its extent depends on the physiological stimulus NO. In regions, where a relatively large NO production signals a high need for local Heart failure perfusion, the chosen PDE5 inhibitor should be Congestive heart failure (CHF) is a chronic debilitat- more efficacious than in areas with lower perfusion ing disease, which leads to infirmity and death demand. In contrast to unspecific vasodilators, within few years. Coronary artery disease, past PDE5 inhibitors trigger a demand-driven increase myocardial infarctions and hypertension are the in flow, which may offer the opportunity for a very major causes of heart failure. specific redistribution of blood flow into areas with There are numerous potential mechanisms by the highest perfusion needs. This may prevent which PDE5 inhibitors could exert positive effects luxury perfusion and steal phenomenon and a on the course and symptoms of this disease. The dramatic decrease in blood pressure. most prominent mechanism is a cGMP-mediated Other effects beyond vascular dilatation have relaxation of smooth muscle cells, which elicits a been described for PDE5 inhibitors, which may also direct vasodilation. Since this is observed primarily have a positive impact on cardiovascular diseases. in the pulmonary vasculature, it may particularly There are numerous reports that describe protective unload the right ventricle. In patients suffering from effects in ischemia/reperfusion in the heart.15 Other CHF, sildenafil decreased pulmonary resistance and authors have reported antihypertrophic,16 antiproli- improved peak oxygen uptake during exercise, ferative,17 and antifibrotic18 efficacy. whereas it did not influence these parameters in healthy volunteers.23 The positive effect of direct vascular dilation may be important in large blood Pulmonary hypertension vessels, since an improved compliance of the large The treatment of pulmonary arterial hypertension is arteries reduces peak ventricular pressure and the most established cardiovascular use of PDE5 improves peripheral perfusion during the diastole International Journal of Impotence Research PDE5 inhibitors beyond erectile dysfunction P Sandner et al 535 by lowering pulse pressure. Such an effect could be stress and smoking. Pharmacological treatments, demonstrated by Hirata et al.24 In patients with however, are often disappointing and inefficient. controlled
Load more

Recommended publications
  • Phosphodiesterase-5 Inhibitors and the Heart: Heart: First Published As 10.1136/Heartjnl-2017-312865 on 8 March 2018
    Heart Online First, published on March 8, 2018 as 10.1136/heartjnl-2017-312865 Review Phosphodiesterase-5 inhibitors and the heart: Heart: first published as 10.1136/heartjnl-2017-312865 on 8 March 2018. Downloaded from compound cardioprotection? David Charles Hutchings, Simon George Anderson, Jessica L Caldwell, Andrew W Trafford Unit of Cardiac Physiology, ABSTRACT recently reported that PDE5i use in patients with Division of Cardiovascular Novel cardioprotective agents are needed in both type 2 diabetes (T2DM) and high cardiovascular Sciences, School of Medical risk was associated with reduced mortality.6 The Sciences, Faculty of Biology, heart failure (HF) and myocardial infarction. Increasing Medicine and Health, The evidence from cellular studies and animal models effect was stronger in patients with prior MI and University of Manchester, indicate protective effects of phosphodiesterase-5 was associated with reduced incidence of new MI, Manchester Academic Health (PDE5) inhibitors, drugs usually reserved as treatments of raising the possibility that PDE5is could prevent Science Centre, Manchester, UK erectile dysfunction and pulmonary arterial hypertension. both complications post-MI and future cardio- PDE5 inhibitors have been shown to improve vascular events. Subsequent similar findings were Correspondence to observed in a post-MI cohort showing PDE5i use Dr David Charles Hutchings, contractile function in systolic HF, regress left ventricular Institute of Cardiovascular hypertrophy, reduce myocardial infarct size and suppress was accompanied with reduced mortality and HF 7 Sciences, The University of ischaemia-induced ventricular arrhythmias. Underpinning hospitalisation. Potential for confounding in these Manchester, Manchester, M13 these actions are complex but increasingly understood observational studies is high, however, and data 9NT, UK; david.
    [Show full text]
  • Effects of Phosphodiesterase Inhibitors on Human Lung Mast Cell and Basophil Function
    British Journal of Pharmacology (1997) 121, 287 ± 295 1997 Stockton Press All rights reserved 0007 ± 1188/97 $12.00 Eects of phosphodiesterase inhibitors on human lung mast cell and basophil function Marie C. Weston, Nicola Anderson & 1Peter T. Peachell Department of Medicine & Pharmacology, University of Sheeld, Royal Hallamshire Hospital (Floor L), Glossop Road, Sheeld S10 2JF 1 The non-hydrolysable cyclic AMP analogue, dibutyryl (Bu2)-cyclic AMP, inhibited the stimulated release of histamine from both basophils and human lung mast cells (HLMC) in a dose-dependent manner. The concentrations required to inhibit histamine release by 50% (IC50) were 0.8 and 0.7 mM in basophils and HLMC, respectively. The cyclic GMP analogue, Bu2-cyclic GMP, was ineective as an inhibitor of histamine release in basophils and HLMC. 2 The non-selective phosphodiesterase (PDE) inhibitors, theophylline and isobutyl-methylxanthine (IBMX) inhibited the IgE-mediated release of histamine from both human basophils and HLMC in a dose-dependent fashion. IBMX and theophylline were more potent inhibitors in basophils than HLMC. IC50 values for the inhibition of histamine release were, 0.05 and 0.2 mM for IBMX and theophylline, respectively, in basophils and 0.25 and 1.2 mM for IBMX and theophylline in HLMC. 3 The PDE 4 inhibitor, rolipram, attenuated the release of both histamine and the generation of sulphopeptidoleukotrienes (sLT) from activated basophils at sub-micromolar concentrations but was ineective at inhibiting the release of histamine and the generation of both sLT and prostaglandin D2 (PGD2) in HLMC. Additional PDE 4 inhibitors, denbufylline, Ro 20-1724, RP 73401 and nitraquazone, were all found to be eective inhibitors of mediator release in basophils but were ineective in HLMC unless high concentrations (1 mM) were employed.
    [Show full text]
  • Mechanisms of Action of PDE5 Inhibition in Erectile Dysfunction
    International Journal of Impotence Research (2004) 16, S4–S7 & 2004 Nature Publishing Group All rights reserved 0955-9930/04 $30.00 www.nature.com/ijir Original Research Mechanisms of action of PDE5 inhibition in erectile dysfunction JD Corbin1* 1Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennesse, USA A spinal reflex and the L-arginine–nitric oxide–guanylyl cyclase–cyclic guanosine monophosphate (cGMP) pathway mediate smooth muscle relaxation that results in penile erection. Nerves and endothelial cells directly release nitric oxide in the penis, where it stimulates guanylyl cyclase to produce cGMP and lowers intracellular calcium levels. This triggers relaxation of arterial and trabecular smooth muscle, leading to arterial dilatation, venous constriction, and erection. Phosphodiesterase 5 (PDE5) is the predominant phosphodiesterase in the corpus cavernosum. The catalytic site of PDE5 normally degrades cGMP, and PDE5 inhibitors such as sildenafil potentiate endogenous increases in cGMP by inhibiting its breakdown at the catalytic site. Phosphorylation of PDE5 increases its enzymatic activity as well as the affinity of its allosteric (noncatalytic/GAF domains) sites for cGMP. Binding of cGMP to the allosteric site further stimulates enzymatic activity. Thus phosphorylation of PDE5 and binding of cGMP to the noncatalytic sites mediate negative feedback regulation of the cGMP pathway. International Journal of Impotence Research (2004) 16, S4–S7. doi:10.1038/sj.ijir.3901205 Keywords: phosphodiesterase inhibitors; vasodilator agents; cyclic GMP; impotence; penile erection Introduction the tone of penile vasculature and the smooth muscle of the corpus cavernosum. In primates, including humans, the L-arginine– In recent years, a deeper understanding of the nitric oxide–guanylyl cyclase–cyclic guanosine regulation of penile smooth muscle has led to monophosphate (cGMP) pathway is the key me- greater insight into the physiology of normal erectile chanism of penile erection1–4 (Figure 1).
    [Show full text]
  • Chapter Introduction
    VU Research Portal Trypanosoma brucei phosphodiesterase B1 as a drug target for Human African Trypanosomiasis Jansen, C.J.W. 2015 document version Publisher's PDF, also known as Version of record Link to publication in VU Research Portal citation for published version (APA) Jansen, C. J. W. (2015). Trypanosoma brucei phosphodiesterase B1 as a drug target for Human African Trypanosomiasis. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 05. Oct. 2021 An introduction into phosphodiesterases and their potential role as drug targets for neglected diseases Chapter 1 4 CHAPTER 1 1.1 Human African Trypanosomiasis Human African Trypanomiasis (HAT), also known as African sleeping sickness, is a deadly infectious disease caused by the kinetoplastid Trypanosoma
    [Show full text]
  • Caffeine and Adenosine
    Journal of Alzheimer’s Disease 20 (2010) S3–S15 S3 DOI 10.3233/JAD-2010-1379 IOS Press Review Article Caffeine and Adenosine Joaquim A. Ribeiro∗ and Ana M. Sebastiao˜ Institute of Pharmacology and Neurosciences, Faculty of Medicine and Unit of Neurosciences, Institute of Molecular Medicine, University of Lisbon, Lisbon, Portugal Abstract. Caffeine causes most of its biological effects via antagonizing all types of adenosine receptors (ARs): A1, A2A, A3, and A2B and, as does adenosine, exerts effects on neurons and glial cells of all brain areas. In consequence, caffeine, when acting as an AR antagonist, is doing the opposite of activation of adenosine receptors due to removal of endogenous adenosinergic tonus. Besides AR antagonism, xanthines, including caffeine, have other biological actions: they inhibit phosphodiesterases (PDEs) (e.g., PDE1, PDE4, PDE5), promote calcium release from intracellular stores, and interfere with GABA-A receptors. Caffeine, through antagonism of ARs, affects brain functions such as sleep, cognition, learning, and memory, and modifies brain dysfunctions and diseases: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Epilepsy, Pain/Migraine, Depression, Schizophrenia. In conclusion, targeting approaches that involve ARs will enhance the possibilities to correct brain dysfunctions, via the universally consumed substance that is caffeine. Keywords: Adenosine, Alzheimer’s disease, anxiety, caffeine, cognition, Huntington’s disease, migraine, Parkinson’s disease, schizophrenia, sleep INTRODUCTION were considered out of the scope of the present work. For more detailed analysis of the actions of caffeine in Caffeine causes most of its biological effects via humans, namely cognition, dementia, and Alzheimer’s antagonizing all types of adenosine receptors (ARs).
    [Show full text]
  • Memory Enhancers for Alzheimer's Dementia
    pharmaceuticals Review Memory Enhancers for Alzheimer’s Dementia: Focus on cGMP Ernesto Fedele 1,2,* and Roberta Ricciarelli 2,3,* 1 Department of Pharmacy, Section of Pharmacology and Toxicology, University of Genoa, 16148 Genova, Italy 2 IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy 3 Department of Experimental Medicine, Section of General Pathology, University of Genoa, 16132 Genova, Italy * Correspondence: [email protected] (E.F.); [email protected] (R.R.) Abstract: Cyclic guanosine-30,50-monophosphate, better known as cyclic-GMP or cGMP, is a classical second messenger involved in a variety of intracellular pathways ultimately controlling different physiological functions. The family of guanylyl cyclases that includes soluble and particulate en- zymes, each of which comprises several isoforms with different mechanisms of activation, synthesizes cGMP. cGMP signaling is mainly executed by the activation of protein kinase G and cyclic nucleotide gated channels, whereas it is terminated by its hydrolysis to GMP operated by both specific and dual-substrate phosphodiesterases. In the central nervous system, cGMP has attracted the attention of neuroscientists especially for its key role in the synaptic plasticity phenomenon of long-term potentiation that is instrumental to memory formation and consolidation, thus setting off a “gold rush” for new drugs that could be effective for the treatment of cognitive deficits. In this article, we summarize the state of the art on the neurochemistry of the cGMP system and then review the pre-clinical and clinical evidence on the use of cGMP enhancers in Alzheimer’s disease (AD) therapy. Although preclinical data demonstrates the beneficial effects of cGMP on cognitive deficits in AD animal models, the results of the clinical studies carried out to date are not conclusive.
    [Show full text]
  • Inhibitors of Cyclic-GMP Phosphodiesterase Alter Excitation of Limulus Ventral Photoreceptors in Ca2+-Dependent Fashion
    The Journal of Neuroscience, October 1995, 75(10): 6586-6591 Inhibitors of Cyclic-GMP Phosphodiesterase Alter Excitation of Limulus Ventral Photoreceptors in Ca2+-Dependent Fashion Edwin C. Johnsonifa and Peter M. O’Day* ‘Department of Physiology, Marshall University School of Medicine, Huntington, West Virginia 257559340 and *Institute of Neuroscience and Department of Biology, University of Oregon, Eugene, Oregon 97403-1254 We have examined the hypothesis that Ca*+-dependent cy- 1994) consistent with the idea that the following events occur clic-GMP metabolism may play a role in visual transduction in phototransduction. Activation of visual pigment, rhodopsin, in Limulus photoreceptors. Although phosphoinositide hy- by light activates a G-protein, stimulating hydrolysis of phos- drolysis is central to phototransduction and phosphoinos- phatidylinositol 4,5-bisphosphate(PIP,) by phospholipaseC; itide-dependent Ca2+-mobilization seems to be required for this createscytosolic inositol 1,4,5trisphosphate(IP,), the trig- transduction, the subsequent steps leading to ion channel ger for mobilization of intracellular Ca2+ and elevation of gating (the immediate cause of excitation) are not under- [CaZ+,].In Limulus photoreceptors,Ca2+-mobilization causes ex- stood. Channels normally opened in response to light can citation by opening plasma membrane channels; however, the be opened in excised membrane patches by cGMP but not link betweenCa*+ elevation and channel gating remainsobscure. by Ca*+, suggesting that cGMP acts as a channel ligand in Electrophysiological evidence implicates cGMP involvement excitation. in Limulus transduction (Johnsonet al., 1986; Bacigalupo et al., Using phosphodiesterase inhibitors, we investigated 1991; Feng et al., 1991). The observation that light-activated whether changes in cGMP metabolism could affect exci- channels are gated selectively by cGMP and not by Ca2+(Ba- tation.
    [Show full text]
  • Repurposing Erectile Dysfunction Drugs Tadalafil and Vardenafil to Increase Bone Mass
    Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone mass Se-Min Kima,b,1, Charit Tanejaa,b, Helena Perez-Penac, Vitaly Ryua,b, Anisa Gumerovaa,b, Wenliang Lic, Naseer Ahmada,b, Ling-Ling Zhua,b, Peng Liua,b, Mehr Mathewa,b, Funda Korkmaza,b, Sakshi Geraa,b, Damini Santa,b, Elina Hadeliaa,b, Kseniia Ievlevaa,b,d, Tan-Chun Kuoa,b, Hirotaka Miyashitaa,b, Li Liue,f, Irina Tourkovae,f, Sarah Stanleyb, Daria Liznevaa,b, Jameel Iqbala,b, Li Suna,b, Ronald Tamlerb, Harry C. Blaire,f, Maria I. Newa,g,1, Shozeb Haiderc, Tony Yuena,b,2, and Mone Zaidia,b,2 aThe Mount Sinai Bone Program, Icahn School of Medicine at Mount Sinai, New York, NY 10029; bDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029; cDepartment of Pharmaceutical and Biological Chemistry, University College London School of Pharmacy, WC1N 1AX London, United Kingdom; dDepartment of Reproductive Health, Scientific Center for Family Health and Human Reproduction Problems, 664003 Irkutsk, Russian Federation; eDepartment of Pathology, Pittsburgh Veterans Affairs Healthcare System, Pittsburgh, PA 15240; fDepartment of Pathology, University of Pittsburgh, Pittsburgh, PA 15261; and gDepartment of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029 Contributed by Maria I. New, April 17, 2020 (sent for review January 27, 2020; reviewed by Yousef Abu-Amer, Fayez F. Safadi, and Mei Wan) We report that two widely-used drugs for erectile dysfunction, bone mass, respectively (18, 19). Likewise, soluble guanylate cy- tadalafil and vardenafil, trigger bone gain in mice through a com- clase has also been targeted for bone gain (20, 21).
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • Gedeon Richter Annual Report Gedeon Richtergedeon • Annual Report • 2011
    GEDEON RICHTER ANNUAL REPORT GEDEON RICHTERGEDEON • ANNUAL REPORT • 2011 1901 2011 00Borito_annual_report_angol_2012_140_old.indd 1 3/25/12 2:29 PM Delivering quality therapy through generations 2011 01_angol_elso_resz_01_66.indd 1 3/26/12 2:23 PM 2 Contents CONTENTS Richter Group – Fact Sheet . 3 Consolidated Financial Highlights . 5 Chairman’s Statement . 7 Directors’ Report . 9 Information for Shareholders . 9 Shareholders’ Highlights . 9 Market Capitalisation . 9 Annual General Meeting . 10 Investor Relations Activities . 10 Dividend . 11 Information Regarding Richter Shares . 12 Shares in Issue . 12 Treasury Shares . 12 Registered Shareholders . 12 Share Ownership by Company Board Members . 13 Risk Management . 14 Corporate Governance . 16 Company’s Boards . 18 Board of Directors . 18 Executive Board . 21 Supervisory Committee . .22 Managing Director’s Review . 25 Operating Review . 29 Consolidated Turnover . 29 Markets – Pharmaceutical Segment . 31 Hungary . 32 International Sales . 34 European Union . 35 CIS . 37 USA . 38 Rest of the World . 38 Wholesale and Retail Activities . 39 Research and Development . 40 Female Healthcare . 42 Products . 46 Manufacturing and Supply . 50 Corporate Social Responsibility . 51 Environmental Policy . 51 Health and Safety at Work . 52 Work Health and Safety Management System . 52 Practical Implementation . 52 Community Involvement . 53 People . 54 Employees . 54 Recruitment and Individual Development . 55 Developing Leaders . 56 Remuneration and Other Employee Programmes . 56 Financial Review . 59 Key Financial Data . 59 Cost of Sales . 59 Gross Profit . 59 Operating Expenses . 60 Profit from Operations . 61 Net Financial Income . 61 Share of Profit of Associates . 62 Income Tax . 62 Profit for the Year . 62 Profit Attributable to Owners of the Parent . 62 Balance Sheet . 63 Cash Flow .
    [Show full text]
  • Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction in Patients with Diabetes Mellitus
    International Journal of Impotence Research (2002) 14, 466–471 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus MA Vickers1,2* and R Satyanarayana1 1Department of Surgery, Togus VA Medical Center, Togus, Maine, USA; and 2Department of Surgery, Division of Urology, University of Massachusetts Medical School, Worcester, Massachusetts, USA Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has become a first-line therapy for diabetic patients with erectile dysfunction (ED). The efficacy in this subgroup, based on the Global Efficacy Question, is 56% vs 84% in a selected group of non-diabetic men with ED. Two novel PDE5 inhibitors, tadalafil (Lilly ICOS) and vardenafil (Bayer), have recently completed efficacy and safety clinical trials in ‘general’ and diabetic study populations and are now candidates for US FDA approval. A summary analysis of the phase three clinical trials of sildenafil, tadalafil and vardenafil in both study populations is presented to provide a foundation on which the evaluation of the role of the individual PDE5 inhibitors for the treatment of patients with ED and DM can be built. International Journal of Impotence Research (2002) 14, 466–471. doi:10.1038=sj.ijir.3900910 Keywords: phosphodiesterase inhibitor; erectile dysfunction; diabetes mellitus; sildenafil; tadalafil; vardenafil Introduction (NO), vasointestinal peptide and prostacyclin, de- creases. Additionally, the endothelial cells that line the cavernosal arteries and sinusoids have a Pathophysiology of ED in diabetes decreased response to nitric oxide due to increased production of advanced glycation end-products and changes associated with insulin resistance.5,6 The Diabetes mellitus is a risk factor for erectile diabetic also experiences a decreased level of dysfunction (ED).
    [Show full text]
  • Rolipram, but Not Siguazodan Or Zaprinast, Inhibits the Excitatory Noncholinergic Neurotransmission in Guinea-Pig Bronchi
    Eur Respir J, 1994, 7, 306–310 Copyright ERS Journals Ltd 1994 DOI: 10.1183/09031936.94.07020306 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neurotransmission in guinea-pig bronchi Y. Qian, V. Girard, C.A.E. Martin, M. Molimard, C. Advenier Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neuro- Faculté de Médecine Paris-Ouest Labora- transmission in guinea-pig bronchi. Y. Qian, V. Girard C.A.E. Martin, M. Molimard, toire de Pharmacologie, Paris, France. C. Advenier. ERS Journals Ltd 1994. ABSTRACT: Theophylline has been reported to inhibit excitatory noncholinergic Correspondence: C. Advenier Faculté de Médecine Paris-Ouest but not cholinergic-neurotransmission in guinea-pig bronchi. As theophylline might Laboratoire de Pharmacologie exert this effect through an inhibition of phosphodiesterases (PDE), and since many 15, Rue de l'Ecole de Médecine types of PDE have now been described, the aim of this study was to investigate the F-75270 Paris Cedex 06 effects of three specific inhibitors of PDE on the electrical field stimulation (EFS) France of the guinea-pig isolated main bronchus in vitro. The drugs used were siguazo- dan, rolipram and zaprinast, which specifically inhibit PDE types, III, IV and V, Keywords: C-fibres respectively. neuropeptides Guinea-pig bronchi were stimulated transmurally with biphasic pulses (16 Hz, 1 phosphodiesterase inhibitors ms, 320 mA for 10 s) in the presence of indomethacin 10-6 M and propranolol 10-6 Received: March 11 1993 M. Two successive contractile responses were observed: a rapid cholinergic con- Accepted after revision August 8 1993 traction, followed by a long-lasting contraction due to a local release of neuropep- tides from C-fibre endings.
    [Show full text]